New York-based venture capital firm Aisling Capital has just raised $280 million for its late-stage clinical biotech companies as it seeks to add on to its most recent successes. Though the $280 million it received this time is less than its previous round of $650 million back in 2009.
One of its more well-known backings is Aimmune Therapeutics, which currently has a $1.4B market cap, and just last year reported positive results from a mid-stage clinical test of its oral immunotherapy AR101. In October, the California biotech announced a deal with Regeneron to test its allergy drug in combination with Sanofi/Regeneron’s Dupixent (dupilumab). Its shares have jumped from $16 this time last year to just below $30 as of yesterday (11/1/17).
In its portfolio, it includes the antifungal immunotherapy and Cidara Therapeutics, sepsis diagnostics maker T2 Biosystems and Seragon Pharmaceuticals, which was acquired by Roche a couple years ago for an upfront amount of $725 million. Also, in September of 2017, it backed early-stage California based biotech company BridgeBio Pharma for its round that raised $135 million.
Aisling Capital reports the $280 million will allow it “to continue helping clinical stage ventures improve global health by more rapidly bringing breakthrough medical treatments to market.”
The VC works by helping life science companies to complete their clinical studies, as well as help guide approval and get its treatment to market.
“We’re extremely excited about the fund’s potential and remain dedicated to increasing the number of quality medical treatments in development across a broad range of therapeutic areas including oncology, aesthetic dermatology, and women’s health,” stated Andrew Schiff, M.D., managing partner at Aisling Capital, in a release. “Over the last 17 years, we’ve helped bring to market some amazing medical innovations and look forward to getting these new treatments into the hands of people who need them as quickly and efficiently as possible.”